Sustainability through remanufacturing in India: a case study on mobile handsets

Remanufacturing activities in India are still in nascent stages. However, the substantial growth of Indian economy, coupled with serious issues of population and environmental burden demands a radical shift in market strategies and legislations. The scattered and inefficient product recovery methods prevalent in India are unable to cope with increasing environmental and economic burden on the society - remanufacturing seems to be a promising strategy to explore for these. Our study investigated from a user's context the opportunity of establishing remanufacturing as a formal activity, answering the fundamental questions of whether remanufactured products would be accepted by Indian consumers and how these will fit into the Indian market. The study of the Indian mobile phone market eco-system showed how mobile phones currently move through the value chain, and the importance of the grey and used phone markets in this movement. A prescriptive model has been proposed which utilizes the usage patterns of different consumer groups to create a self-sustainable demand-supply system, potentially complementing frameworks such as the Automotive Remanufacturing Decision-Making Framework (RDMF). (C) 2011 Elsevier Ltd. All rights reserved.

Analysis of network architectures for zigbee sensor clusters

We provide a comparative performance analysis of network architectures for beacon enabled Zigbee sensor clusters using the CSMA/CA MAC defined in the IEEE 802.15.4 standard, and organised as (i) a star topology, and (ii) a two-hop topology. We provide analytical models for obtaining performance measures such as mean network delay, and mean node lifetime. We find that the star topology is substantially superior both in delay performance and lifetime performance than the two-hop topology.

Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials

Introduction: For over half a century now, the dopamine hypothesis has provided the most widely accepted heuristic model linking pathophysiology and treatment in schizophrenia. Despite dopaminergic drugs being available for six decades, this system continues to represent a key target in schizophrenia drug discovery. The present article reviews the scientific rationale for dopaminergic medications historically and the shift in our thinking since, which is clearly reflected in the investigational drugs detailed. Areas covered: We searched for investigational drugs using the key words `dopamine,' `schizophrenia,' and `Phase II' in American and European clinical trial registers (clinicaltrials. gov; clinicaltrialsregister.eu), published articles using National Library of Medicine's PubMed database, and supplemented results with a manual search of cross-references and conference abstracts. We provide a brief description of drugs targeting dopamine synthesis, release or metabolism, and receptors (agonists/partial agonists/antagonists). Expert opinion: There are prominent shifts in how we presently conceptualize schizophrenia and its treatment. Current efforts are not as much focused on developing better antipsychotics but, instead, on treatments that can improve other symptom domains, in particular cognitive and negative. This new era in the pharmacotherapy of schizophrenia moves us away from the older `magic bullet' approach toward a strategy fostering polypharmacy and a more individualized approach shaped by the individual's specific symptom profile.

Understanding Medical Device Patenting and Clinical Trials for Product Leadership

Unmet clinical needs remain the primary driving force for innovations in medical devices. While appropriate mechanisms to protect these innovative outcomes are essential, the performance of clinical trials to ensure safety is also mandated before the invention is ready for public use. Literature explaining the relationship between patenting activities and clinical trials of medical devices is scarce. Linking patent ownership to clinical trials may imply product leadership and value chain control. In this paper, we use patent data from Indian Patent Office (IPO), PCT, and data from Clinical Trials Registry of India (CTRI) to identify whether patent assignees have any role in leading as primary sponsors of clinical trials. A total of 42 primary sponsors are identified from the CTRI database in India. Number of patents awarded to these primary sponsors in the particular medical device, total number of patents awarded to the primary sponsor in all technologies, total number of patents in the specific medical device technology provides an indication of leadership and control in the value chain.